Show simple item record

dc.contributor.authorSeeto, AH
dc.contributor.authorAbrahamsen, B
dc.contributor.authorEbeling, PR
dc.contributor.authorRodríguez, AJ
dc.date.accessioned2021-09-21T00:59:52Z
dc.date.available2021-09-21T00:59:52Z
dc.date.issued2021
dc.identifier.issn0884-0431
dc.identifier.doi10.1002/jbmr.4157
dc.identifier.urihttp://hdl.handle.net/10072/408125
dc.description.abstractThe cardiovascular safety of denosumab has not yet been evaluated in a systematic review. This systematic review and meta-analysis sought to quantify the number of randomized controlled trials (RCTs) of denosumab (against comparators) reporting cardiovascular adverse events (CAEs) and examine the balance of CAEs between treatment arms. MEDLINE, Embase, and clinicaltrials.gov were searched from inception to October 26, 2019, for RCTs of denosumab versus comparators for any indication. Included trials were randomized, enrolled ≥100 participants, and reported bone-related outcomes. Primary outcome for analysis was all CAEs, a composite endpoint representing summation of all CAEs as reported by included trials. Secondary outcomes included major adverse cardiovascular events (MACE). Data were pooled using a fixed effects model to determine relative risk (RR) and 95% confidence interval (95% CI). Risk of bias was assessed using the Cochrane risk-of-bias tool. Of 554 records screened, 49 were included, while 36 reported CAEs. Twenty-seven included trials (12 eligible for meta-analysis) were conducted in 13,202 postmenopausal women. Compared with bisphosphonates, there was a 46% (95% CI 1.05 to 2.02) increase in CAEs (85/2136 events in denosumab-treated versus 58/2131 events in bisphosphonate-treated; seven trials). There was a similar imbalance in a five-point (stroke, myocardial infarction, cardiovascular death, heart failure, atrial fibrillation) MACE endpoint (28/2053 versus 12/2050; RR = 2.33 [1.19 to 4.56]). Compared with placebo-treated women, there was no imbalance in total CAEs (439/4725 events in denosumab versus 399/4467 in placebo; RR = 0.79 [0.41 to 1.52]; seven trials). No imbalance in total AEs (versus bisphosphonates: 0.98 [0.92 to 1.04]; versus placebo: 0.99 [0.98 to 1.01]) occurred. Other indications showed no statistically significant results. The excess CAEs in postmenopausal women treated with denosumab compared with bisphosphonates, but not placebo, indirectly supports claims that bisphosphonates may suppress CAEs. Future trials should use standardized CAE reporting to better describe cardiovascular effects of bone active medications. (PROSPERO: CRD42019135414.) © 2020 American Society for Bone and Mineral Research (ASBMR).
dc.description.peerreviewedYes
dc.languageeng
dc.publisherWiley
dc.relation.ispartofpagefrom24
dc.relation.ispartofpageto40
dc.relation.ispartofissue1
dc.relation.ispartofjournalJournal of Bone and Mineral Research
dc.relation.ispartofvolume36
dc.subject.fieldofresearchBiological sciences
dc.subject.fieldofresearchEngineering
dc.subject.fieldofresearchHealth sciences
dc.subject.fieldofresearchcode31
dc.subject.fieldofresearchcode40
dc.subject.fieldofresearchcode42
dc.subject.keywordsANTIRESORPTIVES
dc.subject.keywordsCANCER
dc.subject.keywordsCLINICAL TRIALS
dc.subject.keywordsMENOPAUSE
dc.subject.keywordsOSTEOPOROSIS
dc.titleCardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationSeeto, AH; Abrahamsen, B; Ebeling, PR; Rodríguez, AJ, Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials, Journal of Bone and Mineral Research, 2021, 36 (1), pp. 24-40
dcterms.dateAccepted2020-08-02
dc.date.updated2021-09-15T21:13:44Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2021 American Society for Bone and Mineral Research. This is the peer reviewed version of the following article: Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials, Journal of Bone and Mineral Research, 2021, 36 (1), pp. 24-40, which has been published in final form at https://doi.org/10.1002/jbmr.4157. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
gro.hasfulltextFull Text
gro.griffith.authorSeeto, Amanda


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record